arrow
I

I-Wei Ho

台北榮民總醫院
H指数:2
被引数:17

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Response to Comment on “Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort”

对“改良FOLFIRINOX在胰管腺癌中的最佳初始相对剂量强度:一项回顾性多中心队列研究”的评论回复

2026-05-050
OAAI
Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort

改良FOLFIRINOX在胰管腺癌中的最佳初始相对剂量强度:一项回顾性多中心队列研究

2026-04-120
OAAI
SLOG versus Modified FOLFIRINOX as First-Line Treatment for Advanced Pancreatic Cancer: A Randomized Phase II Trial (TCOG T5217)

SLOG与改良FOLFIRINOX作为晚期胰腺癌一线治疗的比较:一项随机II期临床试验(TCOG T5217)

2026-01-110
PRE
Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial

纳米脂质体伊立替康联合5-氟尿嘧啶和亚叶酸钙用于经前期铂类为基础的化疗或放化疗后的晚期头颈及食管鳞状细胞癌:一项多中心II期临床试验

2025-10-210
OAAI